Calliditas Therapeutics AB ADR (CALT): Price and Financial Metrics
CALT Price/Volume Stats
| Current price | $18.58 | 52-week high | $29.30 |
| Prev. close | $18.74 | 52-week low | $15.25 |
| Day low | $17.80 | Volume | 4,422 |
| Day high | $18.67 | Avg. volume | 8,105 |
| 50-day MA | $21.19 | Dividend yield | N/A |
| 200-day MA | $19.46 | Market Cap | 553.50M |
CALT Stock Price Chart Interactive Chart >
Calliditas Therapeutics AB ADR (CALT) Company Bio
Calliditas Therapeutics AB provides pharmaceutical products for patients with niche indications. It focuses on development and commercialization of the product candidate Nefecon intended for treatment of patients with the inflammatory renal disease IgA nephropathy. The company was founded by Mikael Bender and Bengt Åke Julander on February 20, 2004 and is headquartered in Stockholm, Sweden.
Latest CALT News From Around the Web
Below are the latest news stories about CALLIDITAS THERAPEUTICS AB that investors may wish to consider to help them evaluate CALT as an investment opportunity.
Calliditas refinances existing term loan with Euro 92 million senior secured facility with Athyrium CapitalCalliditas Therapeutics AB (Nasdaq: CALT) and (Nasdaq Stockholm: CALTX) ("Calliditas") today announced that the company has signed and fully drawn a term loan of 92 million Euros with funds managed by Athyrium Capital Management, LP ("Athyrium"). Proceeds from the loan will primarily be utilized for full repayment of the company's existing 68 million Euro loan with Kreos Capital. |
Calliditas Therapeutics announces full FDA approval of TARPEYO®, the only FDA-approved treatment for IgA nephropathy to significantly reduce the loss of kidney functionCalliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas"), today announced that the U.S. Food and Drug Administration (FDA) has approved TARPEYO (budesonide) delayed release capsules to reduce the loss of kidney function in adults with primary immunoglobulin A nephropathy (IgAN) at risk for disease progression. TARPEYO was first approved in December 2021 under accelerated approval, based on the surrogate marker of proteinuria. Marking a significant milestone, TARPEYO is |
Calliditas Receives Notice of Allowance for United States Patent Application Covering TARPEYO®Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas") today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for patent application no. 18/100,396 entitled "New Pharmaceutical Compositions." This Notice of Allowance is expected to result in the issuance of a U.S. patent once administrative processes are completed. |
Calliditas announces additions to the management teamCalliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ('Calliditas') today announced that the company has added a new member to its management team, Head of Technical Operations Lars Stubberud. Additionally, the company is welcoming Brian Gorman as its new Group General Counsel. These changes will take effect on 1 January 2024. |
Calliditas initiates clinical study to evaluate setanaxib in Alport SyndromeCalliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ('Calliditas') today announced the initiation of a Phase 2 clinical study to evaluate setanaxib in Alport syndrome. |
CALT Price Returns
| 1-mo | -11.52% |
| 3-mo | -21.80% |
| 6-mo | 6.45% |
| 1-year | -26.56% |
| 3-year | -30.96% |
| 5-year | N/A |
| YTD | -27.83% |
| 2023 | 51.44% |
| 2022 | -31.34% |
| 2021 | -26.35% |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...